Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143957 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
A Phase 2 study of Phlebotomy Dependent Polycythemia Vera, sponsored by Ionis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 13
- Study locations
NCT05143957: Active Phase 2 study of Phlebotomy Dependent Polycythemia Vera, sponsored by Ionis Pharmaceuticals.
NCT05143957 is a Phase 2 study of Phlebotomy Dependent Polycythemia Vera that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05143957, a Phase 2 study of Phlebotomy Dependent Polycythemia Vera, is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 13
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
Conditions Studied
Interventions
- DRUG sapablursen
Study Locations (13)
Other
- Border Medical Oncology Research Unit - Albury
- Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Klinika Hematoonkologii i Transplantacji Szpiku - Lublin
- Wojewódzki Szpital Specjalistyczny Sp. z o.o. - Słupsk
- MICS Centrum Medyczne Toruń - Torun
- University College London Hospitals NHS Foundation Trust - London
Alabama
- O'Neal Comprehensive Cancer Center University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Hospital - Phoenix
New Jersey
- John Theurer Cancer Center - Hackensack
Ohio
- Cleveland Clinic Foundation - Cleveland
Texas
- University of Texas MD Anderson Cancer Center - Houston
New South Wales
- Calvary Mater Newcastle Hospital - Waratah
Quebec
- McGill University Health Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-12-30 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT05143957 still lists
NCT05143957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Phlebotomy Dependent Polycythemia Vera appearing as the primary indexed condition, and to 1 intervention - of which sapablursen is the first listed.
NCT05143957 lists 13 locations in 9 states (Other, Alabama, Arizona).
Frequently Asked Questions
What is clinical trial NCT05143957 about?
NCT05143957 is a clinical study titled "A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera". The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
What is the current status of trial NCT05143957?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-12-30. Estimated completion is 2026-06.
What conditions does trial NCT05143957 study?
This clinical trial studies the following conditions: Phlebotomy Dependent Polycythemia Vera.
What interventions are being tested in trial NCT05143957?
The interventions under investigation include: sapablursen (DRUG).
Who is sponsoring clinical trial NCT05143957?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05143957 being conducted?
This trial has 13 study locations across Alabama, Arizona, New Jersey, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05143957's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI